Project Grant HT94252510783
Award Date
9/30/25
Completion Date
9/29/29
Dollars Obligated
$1.9M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14611, USA
Similar Awards
This federal Project Grant award for $1,173,575.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Rochester to develop an "Anticodon-Edited (ACE) tRNA Treatment of Nonsense-Mediated Duchenne Muscular Dystrophy". The research aims to investigate innovative treatments for Duchenne muscular dystrophy, a debilitating genetic disorder primarily affecting military service members and veterans. The award,...
This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) provides $660,772 to the University of Rochester to conduct research on "Anticodon-Edited (ACE) tRNA Treatment of Nonsense-Mediated Duchenne Muscular Dystrophy". The award period runs from August 1, 2025 to July 31, 2029. The University of Rochester, a leading private research institution, will leverage its expertise in medicine, neuroscience, and advanced...
The University of Rochester received a $769,996 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct spinal cord injury research. The 3-year award, which began on September 1, 2024, will support the University of Rochester's investigator-initiated research on spinal cord injuries. Through this federal grant, the university will deliver scientific research and studies to advance medical treatments and care for...
The University of Rochester was awarded a $1,829,300.00 Project Grant from the U.S. Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, with a performance period from August 1, 2024 to July 31, 2027, will support advanced biomedical research focused on "Mechanistic Insight into the Airborne Hazards Exposure-Related Development of Neurological Disorders." As a leading research university, the...
The University of Rochester received a $812,602 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "IMAGING CANCER MICROENVIRONMENT HOT SPOTS INVOLVED IN PROGRESSION OF MYELODYSPLASTIC SYNDROMES." The research, which will take place from May 2024 to May 2027, aims to improve understanding of the cancer microenvironment and its role in the progression of myelodysplastic syndromes, a group of...
The University of Rochester was awarded a $6,292,954 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "Monitoring and Mitigation of Neurological Injuries to Optimize Resilience After Repetitive Head Impacts (MONITOR RHI)," supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The grant, with a period...
This Project Grant award in the amount of $308,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Rochester. The grant is funding a research project to investigate "INVESTIGATING MICROGLIAL REMODELING OF NEURAL CIRCUITS IN PREGNANCY" over a 2-year period from November 15, 2023 to November 14, 2025. The project aims to advance scientific understanding of the role of microglia, a type of immune...
This $539,400 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports vascular targeted therapy research for Duchenne muscular dystrophy. The grant was awarded to the Regents of the University of Minnesota, a major land-grant research university, to conduct this cutting-edge biomedical research project. The research aims to develop new treatments and advance scientific understanding of this neurological disorder, which...
The University of Rochester will receive $693,000 in funding from the Department of the Army Medical Command through August 31, 2025 for the project "Cooperative Events in the Evolution of Monosomy 7 Myelodysplastic Syndrome." This Project Grant was awarded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for battlefield medicine and other health...
The University of Rochester was awarded a $423,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program by the Defense Health Agency. The grant, titled "ROLE OF INSULINLIKE GROWTH FACTOR BINDING PROTEIN 7 (IGFBP7) IN THE PATHOGENESIS AND TREATMENT OF SCLERODERMA-ASSOCIATED FIBROSIS AND PULMONARY HYPERTENSION", will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public....